Sterling Capital Management’s PTC Therapeutics PTCT Stock Holding History

Sterling Capital Management’s Portfolio PTCT Stock Details PTCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$40.2K	Sell	493 -1,490	-75%	-$108K	﹤0.01%	1639
2026 Q1	$135K	Sell	1,983 -3,298	-62%	-$234K	﹤0.01%	1299
2025 Q4	$401K	Buy	5,281 +92	+2%	+$6.69K	0.01%	1049
2025 Q3	$318K	Buy	5,189 +4,642	+849%	+$242K	﹤0.01%	1173
2025 Q2	$26.7K	Buy	547 +171	+45%	+$8.12K	﹤0.01%	1688
2025 Q1	$19.2K	Sell	376 -269	-42%	-$13.4K	﹤0.01%	1668
2024 Q4	$29.1K	Buy	645 +522	+424%	+$22.3K	﹤0.01%	1765
2024 Q3	$4.56K	Buy	+123	New	+$4.12K	﹤0.01%	1801

Other funds holding PTCT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Sterling Capital Management's PTCT Position: Q2 2026 in Review

Sterling Capital Management reduced its PTC Therapeutics (PTCT) stake by 75% in Q2 2026, selling an estimated $108K and leaving 493 shares worth $40.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1639.

Sterling Capital Management first reported a position in PTCT in Q3 2024 and has held it in 8 quarters since. The position peaked at $401K in Q4 2025. 382 funds tracked by Wall St. Rank hold PTCT as of Q2 2026.

Sterling Capital Management held 493 shares of PTC Therapeutics worth $40.2K as of Q2 2026.
Sterling Capital Management sold 1,490 PTC Therapeutics shares in Q2 2026, an estimated $108K.
PTC Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #1639 holding.
Sterling Capital Management first reported a position in PTC Therapeutics in Q3 2024 and has held it in 8 quarters since.
Sterling Capital Management's PTC Therapeutics position peaked at $401K in Q4 2025.
382 funds tracked by Wall St. Rank held PTC Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.